Hadassah

Clinical Trial at Hadassah Hospital Yields Positive Results With Noninvasive Test for Liver Cancer

Monday, Oct 24 2011

A clinical trial conducted at the Hadassah University Medical Center has revealed that BreathID, a new noninvasive device for the detection of hepato-cellular carcinoma, a type of liver cancer, achieved diagnostic results similar to CT Scans and MRIs. BreathID was developed by Exalenz Bioscience Ltd., whose Medical Director is Prof. Yaron Ilan, Director of Hadassah's Department of Internal Medicine.

The 36 patients in the trial were first checked by ultrasound; those suspected to have liver cancer underwent a CT Scan or MRI, which revealed that 26 patients had the disease. All the patients were then given breath tests with the BreathID device to determine whether it could achieve similar statistically meaningful results. The device achieved a congruence of 93 percent. Exalenz now plans to begin a larger trial of the device, which will involve 100 patients at five hospitals in Israel, the United States, and Canada.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More